MLH1 and cancer: These results suggest the enrichment of BRCA2 mutation as a second hit in non-MLH1 MMRD cancers, but not in MLH1-mutant MMRD cancers, corroborating the synthetic lethality of Brca2 mutant mice on a Mlh1KO/KO background.